Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Nordic Society of Pediatric Hematology and Oncology (NOPHO). / Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only : A NOPHO-AML Study. I: Journal of Pediatric Hematology/Oncology. 2019 ; Bind 41, Nr. 1. s. e12-e17.

Bibtex

@article{4dbf50654022487991feed6a49b4268e,
title = "Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study",
abstract = "BACKGROUND: As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials.PROCEDURE: A population-based cohort of children treated according to the NOPHO-AML-84, NOPHO-AML-88, and NOPHO-AML-93 trials included 137 eligible survivors among whom 101 (74{\%}) completed a questionnaire and 99 (72{\%}) had otologic and audiologic examination performed including otoscopy (72{\%}), pure tone audiometry (70{\%}), and tympanometry (60{\%}). Eighty-four of 93 (90{\%}) eligible sibling controls completed a similar questionnaire.RESULTS: At a median of 11 years (range, 4 to 25) after diagnosis, hearing disorders were rare in survivors of childhood AML and in sibling controls, with no significant differences. None had severe or profound hearing loss diagnosed at audiometry. Audiometry detected a subclinical hearing loss ranging from slight to moderate in 19{\%} of the survivors, 5{\%} had low-frequency hearing loss, and 17{\%} had high-frequency hearing loss.CONCLUSIONS: The frequency of hearing disorders was low, and hearing thresholds in survivors of childhood AML were similar to background populations of comparable age.",
author = "Anne-Sofie Skou and Olsen, {Steen {\O}} and Nielsen, {Lars H} and Heidi Glosli and Kirsi Jahnukainen and Marianne Jarfelt and J{\'o}nmundsson, {Gu{\dh}mundur K} and Johan Malmros and Karsten Nysom and Henrik Hasle and {Nordic Society of Pediatric Hematology and Oncology (NOPHO)}",
year = "2019",
month = "1",
doi = "10.1097/MPH.0000000000001302",
language = "English",
volume = "41",
pages = "e12--e17",
journal = "Journal of Pediatric Hematology / Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only

T2 - A NOPHO-AML Study

AU - Skou, Anne-Sofie

AU - Olsen, Steen Ø

AU - Nielsen, Lars H

AU - Glosli, Heidi

AU - Jahnukainen, Kirsi

AU - Jarfelt, Marianne

AU - Jónmundsson, Guðmundur K

AU - Malmros, Johan

AU - Nysom, Karsten

AU - Hasle, Henrik

AU - Nordic Society of Pediatric Hematology and Oncology (NOPHO)

PY - 2019/1

Y1 - 2019/1

N2 - BACKGROUND: As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials.PROCEDURE: A population-based cohort of children treated according to the NOPHO-AML-84, NOPHO-AML-88, and NOPHO-AML-93 trials included 137 eligible survivors among whom 101 (74%) completed a questionnaire and 99 (72%) had otologic and audiologic examination performed including otoscopy (72%), pure tone audiometry (70%), and tympanometry (60%). Eighty-four of 93 (90%) eligible sibling controls completed a similar questionnaire.RESULTS: At a median of 11 years (range, 4 to 25) after diagnosis, hearing disorders were rare in survivors of childhood AML and in sibling controls, with no significant differences. None had severe or profound hearing loss diagnosed at audiometry. Audiometry detected a subclinical hearing loss ranging from slight to moderate in 19% of the survivors, 5% had low-frequency hearing loss, and 17% had high-frequency hearing loss.CONCLUSIONS: The frequency of hearing disorders was low, and hearing thresholds in survivors of childhood AML were similar to background populations of comparable age.

AB - BACKGROUND: As more children survive acute myeloid leukemia (AML) it is increasingly important to assess possible late effects of the intensive treatment. Hearing loss has only sporadically been reported in survivors of childhood AML. We assessed hearing status in survivors of childhood AML treated with chemotherapy alone according to 3 consecutive NOPHO-AML trials.PROCEDURE: A population-based cohort of children treated according to the NOPHO-AML-84, NOPHO-AML-88, and NOPHO-AML-93 trials included 137 eligible survivors among whom 101 (74%) completed a questionnaire and 99 (72%) had otologic and audiologic examination performed including otoscopy (72%), pure tone audiometry (70%), and tympanometry (60%). Eighty-four of 93 (90%) eligible sibling controls completed a similar questionnaire.RESULTS: At a median of 11 years (range, 4 to 25) after diagnosis, hearing disorders were rare in survivors of childhood AML and in sibling controls, with no significant differences. None had severe or profound hearing loss diagnosed at audiometry. Audiometry detected a subclinical hearing loss ranging from slight to moderate in 19% of the survivors, 5% had low-frequency hearing loss, and 17% had high-frequency hearing loss.CONCLUSIONS: The frequency of hearing disorders was low, and hearing thresholds in survivors of childhood AML were similar to background populations of comparable age.

U2 - 10.1097/MPH.0000000000001302

DO - 10.1097/MPH.0000000000001302

M3 - Journal article

VL - 41

SP - e12-e17

JO - Journal of Pediatric Hematology / Oncology

JF - Journal of Pediatric Hematology / Oncology

SN - 1077-4114

IS - 1

ER -

ID: 56614070